NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia

NCT07168694

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Secondary Progressive Multiple Sclerosis

Countries: United States

The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

* Documented diagnosis of SPMS, with or without relapses.
* Treatment with siponimod for at least 6 months.

Exclusion criteria:

None.

Locations (1)

East Hanover, New Jersey, United States